<div id="readability-page-1"><h3>Easter Sale - 70% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An announcement from MetaVia ( (MTVA) ) is now available. On April 10, 2026, MetaVia Inc. announced it had dosed the first patient in Part 3 of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog targeting GLP-1 and glucagon receptors for the treatment of obesity. The new 16-week study segment in obese but otherwise healthy adults will test one-step titration to 48 mg and two-step titration to 64 mg to refine dosing strategies and safety at higher exposure levels. The Part 3 trial will enroll 40 participants split into two cohorts, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics, alongside metabolic and body composition measures such as weight, waist circumference, BMI, and cardiometabolic markers. MetaVia highlighted earlier Phase 1 data showing around 9% weight loss at 48 mg with favorable tolerability and metabolic benefits, positioning DA-1726 as a potentially differentiated obesity therapy that may reach effective doses more quickly than existing GLP-1-based treatments. The most recent analyst rating on (MTVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page. Spark’s Take on MTVA Stock According to Spark, TipRanks’ AI Analyst, MTVA is a Neutral. The score is primarily held back by weak financial performance (no revenue, ongoing losses and cash burn, and equity erosion) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates around DA-1726 and obesity/MASH positioning provide some support, but valuation remains constrained by ongoing unprofitability. To see Spark’s full report on MTVA stock, click here. More about MetaVia MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, developing novel therapies for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Its lead candidate DA-1726 is a once-weekly subcutaneous dual agonist of GLP-1 and glucagon receptors, while vanoglipel (DA-1241) targets GPR119 to modulate gut peptide release and improve liver and metabolic parameters. DA-1726 has shown best-in-class potential in a Phase 1 multiple ascending dose obesity trial, demonstrating weight loss, improved glucose control, and reductions in waist circumference, and pre-clinical data suggest superior or comparable weight loss and lipid effects versus leading GLP-1-based therapies. Vanoglipel has demonstrated direct hepatic action and favorable effects on liver inflammation, steatosis, fibrosis, and glucose metabolism in pre-clinical and early clinical studies. Average Trading Volume: 258,811 Technical Sentiment Signal: Strong Sell Current Market Cap: $6.06M </div>

SBIO

MetaVia Inc. has announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog aimed at treating obesity. The trial will involve 40 participants and assess safety, tolerability, and metabolic measures over 16 weeks. Previous data indicated a 9% weight loss at 48 mg with favorable tolerability. Despite positive updates, analysts rate MTVA stock as Neutral due to weak financial performance and ongoing losses, with a price target of $8.00.

MetaVia Advances DA-1726 Obesity Trial With First Patient